Skip to main content
Premium Trial:

Request an Annual Quote

Novosom, Isis Pharmaceuticals, Rosetta Genomics

Premium
Novosom Takes Option to License Isis Antisense Drugs
 
Novosom this week said it has acquired an exclusive six-month option to license antisense inhibitors targeting the CD40 membrane protein for all indications from Isis Pharmaceuticals.
 
“CD40 is a validated target for both inflammatory diseases and B-cell cancers,” Novosom said, adding that it would use the antisense drugs to target indications including Crohn's disease, transplants, rheumatoid arthritis, cancer, and multiple sclerosis.
 
The license will give Novosom rights to CD40, as well as oligonucleotides targeting CD40 and incorporating Isis' second-generation antisense chemistry. In exchange, Isis will receive an upfront exercise fee, milestone payments, and royalties.
 

 
Rosetta to Present Cancer Dx Development Data at AACR
 
Rosetta Genomics this week said it will present updated results on its lead diagnostics program for cancer of unknown primary origin at the annual meeting of the American Association for Cancer Research in Los Angeles later this month.
 
The data will be presented in a poster entitled, "MicroRNA Signature for Identification of Tumor Origin" by Nitzan Rosenfeld, team leader of computational biology at Rosetta.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.